国产熟女丝袜av一二区,午夜一区二区三区视频,一级女性全黄久久生活片

首頁(yè)> 產(chǎn)品列表> 咪唑類(lèi)離子液體第一代咪唑離子液體>

Deltarasin HCl

NMR下載 COA and HPLC MSDS下載
names：
2-[4-[(2S)-2-(2-phenyl-1H-benzimidazol-1-yl)-2-(4-piperidinyl)ethoxy]phenyl]-1-(phenylmethyl)-1H-benzimidazole, trihydrochloride
CAS號(hào)：
1440898-82-7
MDL Number：
MF(分子式)： C40H40Cl3N5O MW(分子量)： 713.144
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢(xún)價(jià) 提供各種包裝，敬請(qǐng)垂詢(xún)
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)

快速詢(xún)價(jià)

收起

你想詢(xún)價(jià)的產(chǎn)品

*產(chǎn)品名稱(chēng)：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫(xiě)您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱(chēng)：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢(xún)價(jià)

中文別名	Deltarasin HCl
英文別名	Deltarasin HCl; Deltarasin hydrochloride
CAS號(hào)	1440898-82-7
Inchi	InChI=1S/C40H37N5O.3ClH/c1-3-11-29(12-4-1)27-44-36-17-9-7-15-34(36)42-39(44)32-19-21-33(22-20-32)46-28-38(30-23-25-41-26-24-30)45-37-18-10-8-16-35(37)43-40(45)31-13-5-2-6-14-31;;;/h1-22,30,38,41H,23-28H2;3*1H/t38-;;;/m1.../s1
InchiKey	NCIOVAYUMQEQEU-VKZSUDIWSA-N
分子式 Formula	C40H40Cl3N5O
分子量 Molecular Weight	713.144
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說(shuō)明	Deltarasin HCl(CAS:1440898-82-7 ):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類(lèi)或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。
Introduction	Deltarasin is a high affinity PDEδ-KRAS interaction inhibitor. Deltarasin can inhibit KRAS-PDEδ interactions by binding to a hydrophobic pocket on PDEδ, resulting in the impairment of cell growth, KRAS activity, and RAS/RAF signaling in human pancreatic ductal adenocarcinoma cell lines. The anti-cancer cell activity of deltarasin can be enhanced by simultaneously blocking "tumor protective" autophagy, but inhibited if combined with an anti-oxidant.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Leung ELH, Luo LX, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ, Ward DC, Liu L. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death Dis. 2018 Feb 13;9(2):216. doi: 10.1038/s41419-017-0065-9. PubMed PMID: 29440631; PubMed Central PMCID: PMC5833846.

[2]Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2017 Dec 23. pii: gutjnl-2017-315402. doi: 10.1136/gutjnl-2017-315402. [Epub ahead of print] PubMed PMID: 29275358.

[3] Gulyás G, Radvánszki G, Matuska R, Balla A, Hunyady L, Balla T, Várnai P. Plasma membrane phosphatidylinositol 4-phosphate and 4,5-bisphosphate determine the distribution and function of K-Ras4B but not H-Ras proteins. J Biol Chem. 2017 Nov 17;292(46):18862-18877. doi: 10.1074/jbc.M117.806679. Epub 2017 Sep 22. PubMed PMID: 28939768; PubMed Central PMCID: PMC5704471.

[4] Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE, Nikolouli E, Spiropoulou N, Papadakis A, Papadia K, Voulgaridis A, Harokopos V, Stamou P, Meiners S, Eickelberg O, Snyder LA, Antimisiaris SG, Kardamakis D, Psallidas I, Marazioti A, Stathopoulos GT. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017 May 16;8:15205. doi: 10.1038/ncomms15205. PubMed PMID: 28508873; PubMed Central PMCID: PMC5440809.

[5] Papke B, Murarka S, Vogel HA, Martín-Gago P, Kovacevic M, Truxius DC, Fansa EK, Ismail S, Zimmermann G, Heinelt K, Schultz-Fademrecht C, Al Saabi A, Baumann M, Nussbaumer P, Wittinghofer A, Waldmann H, Bastiaens PI. Identification of pyrazolopyridazinones as PDEδ inhibitors. Nat Commun. 2016 Apr 20;7:11360. doi: 10.1038/ncomms11360. PubMed PMID: 27094677; PubMed Central PMCID: PMC4843002.

6: Zimmermann G, Schultz-Fademrecht C, Küchler P, Murarka S, Ismail S, Triola G, Nussbaumer P, Wittinghofer A, Waldmann H. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. J Med Chem. 2014 Jun 26;57(12):5435-48. doi: 10.1021/jm500632s. Epub 2014 Jun 11. PubMed PMID: 24884780.7: Baker NM, Der CJ. Cancer: Drug for an 'undruggable' protein. Nature. 2013 May 30;497(7451):577-8. doi: 10.1038/nature12248. Epub 2013 May 22. PubMed PMID: 23698372; PubMed Central PMCID: PMC4902159.8: Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI, Waldmann H. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. doi: 10.1038/nature12205. Epub 2013 May 22. PubMed PMID: 23698361.9: Tamanoi F, Lu J. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. Enzymes. 2013;34 Pt. B:181-200. doi: 10.1016/B978-0-12-420146-0.00008-1. Epub 2013 Nov 7. Review. PubMed PMID: 25034105.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開(kāi)

SDS 1.0 英文

展開(kāi)